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Thromboxane Formation and Light-Transmission
Aggregometry in Patients With CAD
(A) Thromboxane (TX) formation in patients with coronary artery disease (CAD)
without aspirin-induced platelet aggregation in light transmission aggregometry
(group A; black bar). Aspirin medication in patients with CAD inhibited TX formation
and platelet aggregation (group B; red bar). Dipyrone comedication with aspirin
restored TX formation sufﬁciently to induce complete platelet aggregation in light
transmission aggregometry in 50% of patients with CAD (group C; blue bar).
*p < 0.05. (B) Exemplary light transmission aggregometry curves (n ¼ 1 per
group). Patients with CAD without aspirin had complete arachidonic acid
(AA)–induced platelet aggregation (group A; black curve). Aspirin inhibited platelet
aggregation in patients with CAD sufﬁciently (group B; red curve). Dipyrone
comedication completely blunted the aspirin-induced inhibition of platelet
aggregation (group C; blue curve).To the Editor: In this letter we report an adverse drug interaction
between aspirin and dipyrone in patients with coronary artery
disease (CAD).
Dipyrone (metamizole) is a widely used nonnarcotic analgesic.
Its common usage is largely due to its favorable clinical effects
in conjunction with a low incidence of gastrointestinal side ef-
fects compared with other nonsteroidal anti-inﬂammatory drugs
(NSAIDs). In Europe, dipyrone daily doses have nearly doubled
since 2005. Aspirin, a unique cost-effective antiplatelet drug, is the
backbone of current clinical practice for secondary prevention of
cardiovascular events and is indispensable after coronary stent
implantation. Aspirin inhibits cyclooxygenase (COX)-1 by ace-
tylating serine 530 near the active site of the enzyme, thus
preventing subsequent thromboxane (TX) formation and TX-
dependent platelet aggregation for the remainder of the platelet’s
life-span. This activity may be hampered by NSAIDs, which
transiently bind to COX-1, thus interfering with the binding of
aspirin to COX-1. Indeed, such interactions have been demon-
strated recently in vitro (1). Increased cardiovascular morbidity and
mortality has been reported in patients treated with NSAIDs (2). It
is not known whether non–anti-inﬂammatory analgesics, such as
dipyrone, have similar effects that might be harmful in patients
with CAD. In this study, we demonstrated that a novel drug-
drug interaction between aspirin and dipyrone occurs in cardiac
patients on continuous low-dose aspirin treatment.
Three subgroups of patients with CAD treated with optimal
medical therapy according to current guidelines were studied.
Group A consisted of 10 patients with CAD in whom aspirin had
been withdrawn because of scheduled cardiac surgery (black curve/
bar; 74  9 years of age). Group B comprised 20 patients with
CAD taking aspirin (red curve/bar; 78  10 years of age). Group C
included 36 patients with a comedication of aspirin/dipyrone (blue
curve/bar; 77  10 years of age). Seventy-ﬁve percent of patients in
groups B and C were on dual antiplatelet therapy with clopidogrel;
none of the patients were on oral anticoagulants (Online Table 1).
In these 66 patients with CAD, platelet function was measured by
arachidonic acid (AA)–induced light transmission aggregometry
and TX B2 formation by immunoassay. AA was used to stimulate
platelet function because it is the only compound that allows
speciﬁc determination of the antiplatelet effects of aspirin in terms
of inhibition of platelet-dependent TX formation (3).
In platelets from patients with CAD not treated with aspirin
(group A) AA induced formation of TX and thus effective platelet
aggregation. TX formation was nearly completely inhibited in
patients treated with aspirin (group B). Dipyrone comedication in
patients with CAD treated with aspirin (group C) restored AA-
induced TX formation to levels sufﬁcient for complete restora-
tion of platelet aggregation (Fig. 1). In group B, aspirin induced
a sufﬁcient inhibition of platelet aggregation in every singleindividual (20 of 20). In contrast, we observed an impaired aspirin
effect in 50% (18 of 36) of dipyrone-comedicated patients with
CAD (group C). This interaction of dipyrone with the antiplatelet
effects of aspirin is most likely due to reversible binding of dipyrone
to platelet COX-1, resulting in steric inhibition of aspirin access to
the active site of COX-1. We have postulated, via ongoing studies
by docking and enzyme kinetic analyses in our laboratory, that
a hydrogen bond between dipyrone and serine 530 as well as steric
blockade of other amino acids like tyrosine 355 and arginine 120
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Consequently, aspirin fails to inhibit platelet COX-1, the phar-
macological target of aspirin (4).
Dipyrone comedication in patients with CAD can completely
blunt the antiplatelet effects of aspirin. This unfavorable phar-
macological drug interaction might result in unexpected treatment
failure and implies several consequences: 1) in future pharma-
cological and interventional trials aiming to modify platelet
function, patients comedicated with dipyrone should be carefully
monitored; 2) analgesic therapy in patients with CAD with
chronic pain should be reevaluated with respect to the use of
NSAIDs and dipyrone; 3) the prescription of dipyrone in patients
on continuous treatment with aspirin undergoing surgery has to
be questioned; and 4) in particular, the use of dipyrone to alleviate
acute pain in the post-operative setting of patients who have
undergone coronary artery bypass graft surgery should be recon-
sidered carefully.
This study investigated a pharmacological aspirin-dipyrone in-
teraction in terms of TX formation and light transmission ag-
gregometry. Point-of-care assays like the VerifyNow assay or the
multiplate analyzer were not used. To establish the clinical impact
of the reported aspirin-dipyrone interaction, randomized trials
with clinical endpoints are needed. (NSAIDs in Coronary Artery
Disease Patients; NCT01402804).*Amin Polzin, MDy
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